P H Scanlon1. 1. Consultant Ophthalmologist, Gloucestershire Eye Unit, Cheltenham General Hospital, Sandford Road, Cheltenham, UK. peter.scanlon@glos.nhs.uk
Abstract
OBJECTIVES: The main objective of the national screening programme is to reduce the risk of sight loss among people with diabetes due to diabetic retinopathy (DR). METHODS: Offering two-field mydriatic digital photographic screening to all people with diabetes in England over the age of 12 years. STAGE OF DEVELOPMENT: The programme is in its infancy, receiving the first year's annual reports from approximately 96 screening programmes, each of which have developed to offer screening to a minimum number of 12,000 people with diabetes, which would cover a population of 350,000 people with 3.4% diabetes prevalence. The national programme has commenced the External quality assurance (QA) programme in order to achieve and sustain the highest possible standards. POTENTIAL BENEFITS: England has a population of two million people with diabetes over the age of 12 and it is believed that there is a prevalence of blindness of 4200 and an annual incidence of blindness of 1280 people with diabetes. This programme has the potential to reduce the prevalence of blindness in England from 4200 people to 1000 people and a conservative estimate of reducing the annual incidence of DR blindness by one-third would save 427 people per annum from blindness. These figures are based on the UK certification of blindness but if World Health Organization (WHO) definitions are used the prevalence, incidence and potential reductions in blindness are much greater.
OBJECTIVES: The main objective of the national screening programme is to reduce the risk of sight loss among people with diabetes due to diabetic retinopathy (DR). METHODS: Offering two-field mydriatic digital photographic screening to all people with diabetes in England over the age of 12 years. STAGE OF DEVELOPMENT: The programme is in its infancy, receiving the first year's annual reports from approximately 96 screening programmes, each of which have developed to offer screening to a minimum number of 12,000 people with diabetes, which would cover a population of 350,000 people with 3.4% diabetes prevalence. The national programme has commenced the External quality assurance (QA) programme in order to achieve and sustain the highest possible standards. POTENTIAL BENEFITS: England has a population of two million people with diabetes over the age of 12 and it is believed that there is a prevalence of blindness of 4200 and an annual incidence of blindness of 1280 people with diabetes. This programme has the potential to reduce the prevalence of blindness in England from 4200 people to 1000 people and a conservative estimate of reducing the annual incidence of DR blindness by one-third would save 427 people per annum from blindness. These figures are based on the UK certification of blindness but if World Health Organization (WHO) definitions are used the prevalence, incidence and potential reductions in blindness are much greater.
Authors: Amber A W A van der Heijden; Iris Walraven; Esther van 't Riet; Thor Aspelund; Sigrún H Lund; Petra Elders; Bettine C P Polak; Annette C Moll; Jan E E Keunen; Jacqueline M Dekker; Giel Nijpels Journal: Diabetologia Date: 2014-04-26 Impact factor: 10.122
Authors: Shuwen He; Zhixiong Ye; Quang Truong; Shrenik Shah; Wu Du; Liangqin Guo; Peter H Dobbelaar; Zhong Lai; Jian Liu; Tianying Jian; Hongbo Qi; Raman K Bakshi; Qingmei Hong; James Dellureficio; Alexander Pasternak; Zhe Feng; Reynalda deJesus; Lihu Yang; Mikhail Reibarkh; Scott A Bradley; Mark A Holmes; Richard G Ball; Rebecca T Ruck; Mark A Huffman; Frederick Wong; Koppara Samuel; Vijay B Reddy; Stan Mitelman; Sharon X Tong; Gary G Chicchi; Kwei-Lan Tsao; Dorina Trusca; Margaret Wu; Qing Shao; Maria E Trujillo; George J Eiermann; Cai Li; Bei B Zhang; Andrew D Howard; Yun-Ping Zhou; Ravi P Nargund; William K Hagmann Journal: ACS Med Chem Lett Date: 2012-05-07 Impact factor: 4.345
Authors: T Aspelund; O Thornórisdóttir; E Olafsdottir; A Gudmundsdottir; A B Einarsdóttir; J Mehlsen; S Einarsson; O Pálsson; G Einarsson; T Bek; E Stefánsson Journal: Diabetologia Date: 2011-07-27 Impact factor: 10.122
Authors: Krystal Khoo; Ryan E K Man; Gwyn Rees; Preeti Gupta; Ecosse L Lamoureux; Eva K Fenwick Journal: Qual Life Res Date: 2019-03-16 Impact factor: 4.147